Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

• Published in: Neuro-oncology (Charlottesville, Va.) Vol. 19; no. 11; pp. 1469 - 1480
• Main Authors: McNeill, Robert S, Canoutas, Demitra A, Stuhlmiller, Timothy J, Dhruv, Harshil D, Irvin, David M, Bash, Ryan E, Angus, Steven P, Herring, Laura E, Simon, Jeremy M, Skinner, Kasey R, Limas, Juanita C, Chen, Xin, Schmid, Ralf S, Siegel, Marni B, Van Swearingen, Amanda E D, Hadler, Michael J, Sulman, Erik P, Sarkaria, Jann N, Anders, Carey K, Graves, Lee M, Berens, Michael E, Johnson, Gary L, Miller, C Ryan
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 19.10.2017
• Subjects: Animals; Apoptosis - drug effects; Basic and Translational Investigations; Brain Neoplasms - drug therapy; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Cell Proliferation - drug effects; Drug Resistance, Neoplasm; Drug Synergism; Glioblastoma - drug therapy; Glioblastoma - metabolism; Glioblastoma - pathology; Humans; Mice; Mitogen-Activated Protein Kinases - antagonists & inhibitors; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors - pharmacology; Signal Transduction - drug effects; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; glioblastoma; kinase inhibitors; PI3K; MAPK; genetically engineered mice
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/nox044

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Prognosis remains poor despite multimodal therapy. Developing alternative treatments is essential. Drugs targeting kinases within the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) effectors of receptor tyrosine kinase (RTK) signaling represent promising candidates. We previously developed a non-germline genetically engineered mouse model of GBM in which PI3K and MAPK are activated via Pten deletion and KrasG12D in immortalized astrocytes. Using this model, we examined the influence of drug potency on target inhibition, alternate pathway activation, efficacy, and synergism of single agent and combination therapy with inhibitors of these 2 pathways. Efficacy was then examined in GBM patient-derived xenografts (PDX) in vitro and in vivo. PI3K and mitogen-activated protein kinase kinase (MEK) inhibitor potency was directly associated with target inhibition, alternate RTK effector activation, and efficacy in mutant murine astrocytes in vitro. The kinomes of GBM PDX and tumor samples were heterogeneous, with a subset of the latter harboring MAPK hyperactivation. Dual PI3K/MEK inhibitor treatment overcame alternate effector activation, was synergistic in vitro, and was more effective than single agent therapy in subcutaneous murine allografts. However, efficacy in orthotopic allografts was minimal. This was likely due to dose-limiting toxicity and incomplete target inhibition. Drug potency influences PI3K/MEK inhibitor-induced target inhibition, adaptive kinome reprogramming, efficacy, and synergy. Our findings suggest that combination therapies with highly potent, brain-penetrant kinase inhibitors will be required to improve patient outcomes.